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Orphan receptor IL-17RD regulates Toll-like
receptor signalling via SEFIR/TIR interactions
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John J. Callanan3 & Paul N. Moynagh1,4
Receptor families of the innate immune response engage in ‘cross-talk’ to tailor optimal
immune responses against invading pathogens. However, these responses are subject to
multiple levels of regulation to keep in check aberrant inflammatory signals. Here, we
describe a role for the orphan receptor interleukin-17 receptor D (IL-17RD) in negatively
regulating Toll-like receptor (TLR)-induced responses. Deficiency of IL-17RD expression in
cells leads to enhanced pro-inflammatory signalling and gene expression in response to TLR
stimulation, and Il17rd / mice are more susceptible to TLR-induced septic shock. We
demonstrate that the intracellular Sef/IL-17R (SEFIR) domain of IL-17RD targets TIR adaptor
proteins to inhibit TLR downstream signalling thus revealing a paradigm involving cross-
regulation of members of the IL-17R and TLR families.
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T
he innate immune system has evolved a panoply of
pattern-recognition receptors, including the transmem-
brane TLR family, to detect infection by recognizing highly
conserved pathogen-associated molecular patterns, that are not
found on host cells1. TLRs contain extracellular leucine-rich
repeats that are integral in pathogen-associated molecular pattern
binding, and a highly conserved intracellular domain that is
shared with the interleukin (IL)-1 receptor family, the
Toll/interleukin-1 receptor (TIR) domain2,3. The TIR domain is
critical for recruiting one or more TIR-containing adaptor
proteins to the plasma membrane to initiate downstream
signalling pathways, resulting in activation of mitogen-activated
protein kinases (MAPKs), NF-kB and interferon regulatory
factors (IRFs), which promote transcription of pro-
inflammatory genes.
MyD88, the first TIR domain-containing adaptor to be
characterized, is universally recruited by the IL-1 receptor family
and all TLRs, except TLR3, for NF-kB activation4. MyD88-
deficient mice still possess the ability to activate NF-kB, albeit
with delayed kinetics, in response to lipopolysaccharide (LPS) and
synthetic double-stranded RNA polyinosinic–polycytidylic acid
(poly(I:C)), ligands for TLR4 and TLR3, respectively, indicating
the existence of a MyD88-independent pathway for these
receptors5–7. The discovery of Mal (or TIRAP) revealed that
TLR2 and TLR4 bind MyD88 by employing Mal as a bridging
adaptor8–11. Searches of the human genome for other TIR-
containing proteins unveiled three more adaptors: TRIF, TRAM
and SARM12–14. TRIF was revealed to be the adaptor utilized by
TLR3 in NF-kB and IRF signalling12. TRIF is engaged directly by
TLR3, but TLR4 requires a bridging adaptor and signals through
TRIF by interacting primarily with TRAM14–17. SARM fails to
activate NF-kB or IRF3 and has been described as a specific
inhibitor of TRIF-dependent signalling18,19.
MyD88 can activate downstream NF-kB and MAPK pathways
by recruiting IRAK family members, which facilitate activation of
the E3 ubiquitin ligase TRAF6 (refs 20–22). Formation of
polyubiquination chains by TRAF6 acts as a platform for TAK1
to interact with its target substrates, the IkB kinases (IKKs),
which subsequently phosphorylate the NF-kB inhibitor, IkB,
leading to its proteasomal degradation and the subsequent release
of NF-kB to the nucleus, where it activates transcription of pro-
inflammatory genes23. TRAF6 also associates with TRIF and
mediates NF-kB activation, although some reports suggest that
RIP1 kinase is more important for this process24–28. TRIF also
triggers IRF3 and IRF7 activation via the non-canonical IKK
kinases, IKKi and TBK1, which phosphorylate IRF3 and IRF7 on
serine residues, leading to their translocation to the nucleus and
induction of type-I interferons (IFNs)29,30.
Of increasing importance to the tailoring of innate immune
responses initiated by TLRs, is the ability of innate immune
signalling pathways to engage in ‘cross-talk’ to promote optimal
immune responses. Recently, it was reported that the Sef/IL-17R
(SEFIR) domains of the IL-17 receptors and the TIR domain of
TLRs (which constitute a STIR domain superfamily) share
similarity in length and secondary structure, especially in highly
conserved boxes 1 and 2 of the TIR domain31. However, to date
no data have been presented to implicate a functional interaction
of these related domains. We have recently characterized the
function of the orphan IL-17 receptor D (IL-17RD) in
differentially regulating IL-17A-induced NF-kB and MAPK
pathways32. The Il17rd gene encodes a transmembrane protein
of the IL-17 receptor family, but its ligand remains unidentified33.
IL-17RD, originally termed similar expression to fibroblast growth
factor ( fgf ) genes (Sef) as it belonged to the FGF synexpression
group in zebrafish development34,35, was initially established as a
negative regulator of FGF-induced Ras and MAPK signalling
pathways in zebrafish, and subsequently mammalian IL-17RD was
reported to inhibit ERK and PI3K pathways in response to a
number of receptor tyrosine kinase ligands36–41.
We now show that IL-17RD is a negative regulator of both
NF-kB and IRF signalling pathways initiated by TLRs. The SEFIR
domain of IL-17RD targets the TIR adaptors, MyD88, Mal, TRIF
and TRAM, and strongly inhibits TLR-mediated activation of
NF-kB with IL-17RD deficiency leading to increased NF-kB and
IRF activation and upregulation of pro-inflammatory genes.
Il17rd / mice are more susceptible to TLR4- and TLR3-
induced septic shock. We also present evidence for an
autoregulatory feedback system in which IL-17RD targets TIR
adaptors in a TLR stimulation-dependent manner thus preclud-
ing recruitment of the downstream effector TRAF6 and limiting
pro-inflammatory gene expression. These findings describe a new
regulatory network involving the functional interplay of members
of the IL-17R and TLR families.
Results
IL-17RD inhibits TLR-induced signalling and gene expression.
Most TIR and SEFIR domain-containing proteins have the ability
to trigger the activation of NF-kB. However, whereas the TIR
adaptor proteins MyD88, Mal, TRIF and TRAM were capable of
inducing an NF-kB-regulated luciferase reporter plasmid in
HEK293 cells, overexpression of IL-17RD was ineffective
(Supplementary Fig. 1a). In addition, overexpression of IL-17RD
failed to induce IRF3 (Supplementary Fig. 1b) and IRF7
(Supplementary Fig. 1c) activation, unlike the upstream reg-
ulators IKKi and TBK1. Given the lack of effect of IL-17RD, we
next probed its potential regulatory effects on TLR signalling.
Co-transfection of cells with IL-17RD caused a dose-dependent
inhibition of MyD88-, Mal-, TRIF- and TRAM-mediated
induction of NF-kB-regulated luciferase (Fig. 1a). IL-17RD was
also capable of inhibiting TRIF-induced expression of IRF3- and
IRF7-regulated luciferase (Fig. 1b). We next explored the
regulatory effects of IL-17RD on the induction of NF-kB and
IRF-responsive genes. MyD88, Mal, TRIF and TRAM induced
high levels of IL-8 production and this induction was inhibited by
IL-17RD in a dose-dependent manner (Fig. 1c). TRIF induction
of RANTES expression was also diminished in the presence of
IL-17RD (Fig. 1d). To further explore the role of endogenous
IL-17RD in TLR signalling, Il17rd gene expression was silenced
by IL-17RD-specific small interfering RNA (siRNA) (previously
described32; Supplementary Fig. 1d, inset). Silencing of Il17rd
gene expression in HEK293 cells resulted in augmented NF-kB
activation in response to LPS and poly(I:C), while a scrambled
control siRNA had no effect (Supplementary Fig. 1d). To validate
these findings in other cell types, we established U373 and THP-1
cell lines that were selected for stable integration of lentivirus
encoding IL-17RD-specific short hairpin RNA (shRNA) or
control shRNA. Forty to sixty percent knockdown of Il17rd
gene expression was consistently observed in U373 and THP-1
stable cell lines (Supplementary Fig. 1f). Knockdown of IL-17RD
expression resulted in enhanced tumour necrosis factor-a
(TNF-a) and IL-8 production in response to LPS, in U373 and
THP-1 cells, respectively (Fig. 1e,f), and augmented poly(I:C)-
induced RANTES and IP-10 production in U373 cells (Fig. 1g).
This effect was mediated by increased gene expression,
as LPS and poly(I:C) induced greater amounts of Il8 and Ifnb1
messenger RNA (mRNA) in THP-1 and U373 cells, respectively,
stably expressing IL-17RD-specific shRNA (Supplementary
Fig. 1g,h). These findings indicated that IL-17RD negatively
regulates the expression of TLR3- and TLR4-responsive genes.
This was further validated in human primary cells. Peripheral
blood mononuclear cells (PBMCs) were isolated from blood of
healthy volunteers and transfected with IL-17RD-specific and
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scrambled siRNAs. Knockdown of Il17rd gene expression
in PBMCs (Supplementary Fig. 1i) augmented LPS- and
poly(I:C)-induced expression of IL-8 and IFN-b production
(Supplementary Fig. 1j). Given that IL-17RD regulated the levels
of gene transcription, we next assessed its effects on the upstream
signalling pathways that regulate such gene expression.
Knockdown of IL-17RD in THP-1 cells (Fig. 1h, inset panel)
resulted in enhanced LPS-induced phosphorylation of IkBa
and IKKs in response to LPS (Fig. 1h). Poly(I:C)-induced
phosphorylation of IRF3 and its upstream kinase TBK1 was
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Figure 1 | IL-17RD negatively regulates TLR signalling pathways. (a,b) Assay of NF-kB-regulated luciferase reporter activity in HEK293 cells transfected
with Myc-tagged IL-17RD (0–100ng) and (a) MyD88, Mal, TRIF or TRAM (50 ng) with a NF-kB luciferase reporter plasmid (60 ng) or (b) with TRIF
(50 ng) and PFR-luciferase (60 ng) with IRF3-Gal4 (30 ng) or IRF7-Gal4 (25 ng) constructs. TK Renilla was measured to determine transfection efficiency.
(c,d) Supernatants were measured for (c) IL-8 or (d) RANTES production by sandwich ELISA. (e,f) ELISA of (e) TNF-a or (f) IL-8 from U373 or THP-1 cells,
respectively, previously transduced with lentiviral-encoded control or IL-17RD-specific shRNA and treated with LPS (100 ngml 1) for 24 h.
(g) Supernatants from U373 cells stably transduced with control or IL-17RD-specific shRNA measured for RANTES and IP-10 levels by ELISA in response to
poly(I:C) (25mgml 1). (h,i) Cell lysates from (h) THP-1 cells treated with LPS (100 ngml 1) for 0, 5, 15, 30, 60 and 240min and (i) U373 cells treated
with poly(I:C) (25mgml 1) for 0, 45, 90, 120, 240 and 360min, both stably expressing control and IL-17RD-specific shRNA, were subjected to
immunoblotting with indicated antibodies. (h,i: inset panels) Cell lysates from THP-1 and U373 cells expressing control (Ctrl) or IL-17RD-specific shRNA
(shRNA) were analysed for IL-17RD and b-actin expression with specific antibodies by immunoblotting. Overexpressed IL-17RD (oe) was used as a control
from HEK293 and U373 cell lysates, respectively. Data are presented (a–g) as the mean±s.e.m. of three independent experiments and were subjected to
a two-tailed paired Student’s t-test, *Po0.05; **Po0.01 or (h,i) are representative of three independent experiments. Images have been cropped for
presentation. Full-size images are presented in Supplementary Fig. 7.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7669 ARTICLE
NATURE COMMUNICATIONS | 6:6669 | DOI: 10.1038/ncomms7669 |www.nature.com/naturecommunications 3
& 2015 Macmillan Publishers Limited. All rights reserved.
also accelerated and augmented in U373 cells expressing IL-
17RD-specific shRNA compared with control cells (Fig. 1i),
indicating that IL-17RD targets upstream regulators in these
signal transduction pathways.
IL-17RD deficiency enhances cell responsiveness to TLRs. The
above overexpression and knockdown studies strongly suggest
that IL-17RD is a negative regulator of TLR adaptor-induced
signalling. To confirm the physiological relevance of such
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findings, bone marrow-derived macrophages (BMDMs) from
wild-type and IL-17RD-deficient mice32 were compared for their
responsiveness with various TLR ligands. All of the TLR ligands
induced IL-6 protein in wild-type BMDMs, but the levels of
induction were further enhanced in IL-17RD-deficient cells
(Fig. 2a). Similarly, the levels of LPS- and poly(I:C)-induced
RANTES (Fig. 2b) and poly(I:C)-induced IFN-b production
(Fig. 2c) were greater in Il17rd / macrophages. Given the
enhanced expression of TLR-responsive genes in IL-17RD-
deficient cells, we were keen to assess gene expression in
response to a live pathogen that triggers these pathways.
Murine embryonic fibroblasts (MEFs) from wild-type and
Il17rd / embryos were infected with encephalomyocarditis
virus (EMCV) and expression levels of pro-inflammatory
cytokines and chemokines were measured. EMCV induced IL-6,
KC and RANTES production in wild-type MEFs, but levels of
induction were greater in IL-17RD-deficient cells (Supplementary
Fig. 2a). The greater expression of TLR- and EMCV-responsive
genes in IL-17RD-deficient cells seems to be due to regulatory
effects on gene transcription as indicated by enhanced LPS-
induced expression of Cxcl1 and Il6 mRNAs (Supplementary
Fig. 2b) and EMCV-induced Ifnb1 mRNA in Il17rd / cells
relative to wild-type counterparts (Supplementary Fig. 2c).
Given that the effects of IL-17RD deficiency on TLR-
responsive gene expression manifest as changes in their levels
of transcription, we next characterized the upstream signalling
pathways that regulates such transcription. LPS-induced phos-
phorylation of IkBa, IKK and IRF3 was accelerated and more
pronounced in IL-17RD-deficient BMDMs compared with wild-
type cells (Fig. 2d), suggesting that loss of IL-17RD leads to
greater activation of NF-kB and IRF3. This was confirmed by
electromobility-shift assays (EMSAs) in which nuclear extracts
from LPS-stimulated Il17rd / BMDMs (Fig. 2e) and Il17rd /
MEFs (Supplementary Fig. 2d) showed more binding, than
extracts from corresponding wild-type cells, to an oligonucleotide
containing the NF-kB recognition motif. The enhanced activation
of NF-kB and IRF3 in the absence of IL-17RD also extended to
the TLR3 pathway, since poly(I:C)-mediated phosphorylation of
IRF3, IkBa and IKKs (Fig. 2f) and IRF3/IRF7 binding to the
enhancer region of the Ifnb1 gene (Fig. 2g) were more intense in
Il17rd / cells relative to wild-type cells. Given that IL-17RD
was initially characterized as a negative regulator of FGF-induced
ERK signalling, we also assessed the effects of IL-17RD deficiency
on activation of the ERK pathway in response to LPS. Under
these conditions, the levels of ERK phosphorylation were
increased basally and in LPS-stimulated IL-17RD-deficient MEFs
(Supplementary Fig. 3a) and bone marrow-derived dendritic cells
(BMDCs) (Supplementary Fig. 3b), suggesting that IL-17RD
negatively regulates LPS-induced activation of ERKs.
To validate that enhanced TLR responses in cells lacking
IL-17RD are directly attributable to loss of IL-17RD expression,
we transduced IL-17RD-deficient MEFs with retrovirus encoding
murine Myc-tagged IL-17RD or an empty vector. Reconstitution
of Il17rd / MEFs with mIL-17RD reduced LPS-induced
phosphorylation of IkBa and IKKs (Fig. 2h) and poly(I:C)-
induced phosphorylation of TBK1 and IRF3 (Fig. 2i) to levels
comparable to wild-type cells. Furthermore, reconstitution of cells
with mIL-17RD also reduced the efficacy of LPS and poly(I:C) in
driving expression of IL-6 and IFN-b (Fig. 2j).
IL-17RD-deficient mice are more susceptible to septic shock.
The above cell-based approaches demonstrate that a loss of
IL-17RD expression results in a heightened pro-inflammatory
response to TLR ligands. We next investigated the in vivo
relevance of such effects. Wild-type and Il17rd / mice were
challenged with LPS by intraperitoneal (i.p.) injection and
assessed for systemic inflammation. LPS induced lethality in 37%
of wild-type mice, but this increased to 81% in the case of
IL-17RD-deficient mice with death also being evident at earlier
times post LPS administration (Fig. 3a). Lower resistance of
Il17rd / mice to TLR4-induced septic shock correlated with
significantly increased serum concentrations of IL-6, KC and the
IL-12/IL-23 p40 subunit in IL-17RD-deficient mice challenged
with LPS for 16 h compared with wild-type mice (Fig. 3b).
Transcription of the genes encoding inducible nitric oxide syn-
thase (iNOS), TNF-a and IL-6 were also substantially upregulated
in the spleen of Il17rd / mice compared with wild-type mice
in response to LPS (Fig. 3c). To determine whether Il17rd /
mice were also more susceptible to TLR3-induced death, mice
were subjected to i.p. injection of poly(I:C) co-administered with
a liver-specific transcription inhibitor, D-galactosamine (D-GAL),
to enhance toxicity42 (Fig. 3d). A low dose of poly(I:C) with
D-GAL induced death in less than 20% of wild-type mice in 24 h;
however, 50% of Il17rd / mice succumbed to poly(I:C)-
induced death. Examination of liver tissue from surviving
poly(I:C)-treated wild-type mice by microscopy revealed
histopathological changes with normal liver architecture, mild
hepatocyte vacuolation and occasional individual necrotic cells
(Fig. 3e). In contrast, surviving Il17rd / mice showed distorted
liver architecture due to widespread areas of necrosis,
characterized by pyknotic nuclei, with pooling of red blood
cells from the sinuses. Consistent with lethality results, serum
concentrations of IFN-b, RANTES, IL-6 and the IL-12/IL-23 p40
Figure 2 | IL-17RD deficiency enhances cell responsiveness to TLRs. (a–c) BMDMs from wild-type (WT) and Il17rd / mice were stimulated with
(a) Pam2Cys (100 ngml 1), Pam3Cys (100 ngml 1), Zymosan (1 mgml 1), poly(I:C) (5mgml 1), LPS (10 ngml 1), CL097 (1 mgml 1) and CpG
(5mgml 1), (b) poly(I:C) (5mgml 1) and LPS (10 ngml 1) for 24 h or (c) poly(I:C) (5 mgml 1) for 24 h. Conditioned media was assayed for (a) IL-6,
(b) RANTES or (c) IFN-b. (d,f) WT and Il17rd / BMDMs were treated with (d) LPS (10 ngml 1) or (f) poly(I:C) (5 mgml 1) for 0–240min and cell
lysates immunoblotted with indicated antibodies. (d, inset panel) Cell lysates fromWTand Il17rd / BMDCs were immunoblotted for IL-17RD and b-actin
expression. (e) WTand Il17rd / BMDMs were stimulated with LPS (10 ngml 1) for 0–120min and nuclear extracts assayed by EMSA for NF-kB/DNA
binding. Nuclear extracts (from Il17rd / cells stimulated with LPS for 60min) were also pre-incubated for 15min with 1 mg anti-p65 antibody (ss;
supershift) or IgG control (IgG). (g) WTand Il17rd / BMDCs were stimulated with poly(I:C) (5mgml 1) for 0–120min and nuclear extracts assayed by
EMSA using an oligonucleotide containing the PRD I/III domain of the Ifnb1 promoter. Nuclear extracts (from Il17rd / cells stimulated with poly(I:C) for
30min) were also pre-incubated for 15min with an unlabelled competitor oligonucleotide. (h–j) WT and Il17rd / MEFs were infected with MSCV
retroviral particles containing an empty vector (EV) plasmid or wild-type mIL-17RD-Myc (Il17rd / MEFs) for 72 h. Cells were treated with (h) LPS
(100 ngml 1) or (i) poly(I:C) (25mgml 1) for 0–60min and cell lysates immunoblotted with indicated antibodies or cells were treated with (j) LPS
(100 ngml 1) or poly(I:C) (25mgml 1) for 24 h and conditioned media assayed for levels of IL-6 and IFN-b. Data are presented (a–c,j) as the
mean ±s.e.m. of three independent experiments and were subjected to a two-tailed paired Student’s t-test, *Po0.05; **Po0.01 or (d–i) are
representative of three independent experiments. Images have been cropped for presentation. Full-size images are presented in Supplementary Fig. 8.
NS, not significant.
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and IL-17RD-Myc (1mg). Cell lysates were immunoprecipitated with an anti-FLAG antibody, followed by immunoblotting with indicated antibodies.
(b) HEK293 cells were transfected for 24 h with MyD88-GFP and IL-17RD-RFP and visualized for expression and localization using confocal microscopy.
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(c) HEK293 cells were transfected for 24 h with MyD88-FLAG with IL-17RD-Myc or IL-17RD DC-Myc (1 mg). Cell lysates were immunoprecipitated with an
anti-FLAG antibody, followed by immunoblotting with indicated antibodies. (d) Assay of NF-kB-regulated luciferase expression in HEK293 cells transfected
with MyD88 (50 ng) with IL-17RD-Myc or IL-17RD DC-Myc (50 ng). (e–g) HEK293 cells were transfected for 24 h with (e) TLR4-FLAG and IL-17RD-Myc or
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paired Student’s t-test. *Po0.05. Images have been cropped for presentation. Full-size images are presented in Supplementary Fig. 9.
NS, not significant.
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Figure 5 | IL-17RD disrupts signalling downstream of TIR adaptors. (a) WT and Il17rd / BMDMs were stimulated for 0, 5, 20 and 60min with LPS
(10 ngml 1) and cell lysates were subject to immunoprecipitation with an anti-MyD88 antibody and subjected to immunoblotting with indicated
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subunit were greatly augmented in Il17rd / mice compared
with wild-type mice after 16 h of poly(I:C) challenge (Fig. 3f). The
enhanced type-I IFN in serum of Il17rd / mice was bioactive
(Fig. 3g). Poly(I:C)-mediated transcription of Cxcl10 and Ccl5
genes were also increased in spleens from Il17rd / mice
compared with wild-type mice (Fig. 3h). Overall these findings
provide strong support for a physiological role for IL-17RD in
negatively regulating the host response to stimulation of TLR3
and TLR4.
SEFIR domain is critical for inhibitory effects of IL-17RD.
The important regulatory role of IL-17RD in dampening the
TLR-induced inflammatory response prompted studies on the
mechanism by which IL-17RD exerts its inhibitory function.
Given that IL-17RD contains a SEFIR domain, which shares some
structural similarity with the TIR domain31, and our earlier
observations that IL-17RD inhibits signalling downstream of
TIR adaptors, we examined whether IL-17RD could target
TIR adaptors as part of their inhibitory function. Co-
immunoprecipitation analysis demonstrated that IL-17RD can
interact with co-expressed MyD88 or Mal (Fig. 4a). The ability of
IL-17RD to interact with these TIR adaptors was further
supported by confocal microscopy revealing co-localization of
IL-17RD and MyD88 in cytoplasmic vesicle structures (Fig. 4b).
We next investigated whether the SEFIR domain was required for
this interaction. A truncation mutant of IL-17RD lacking the
C-terminal SEFIR domain, termed IL-17RDDC, was thus
generated (Supplementary Fig. 4a) and assessed for ability to
interact with MyD88 by co-immunoprecipitation analysis. Unlike
full-length IL-17RD, IL-17RDDC failed to show any detectable
interaction with MyD88 (Fig. 4c). Furthermore, IL-17RDDC was
unable to inhibit MyD88-activation of NF-kB (Fig. 4d),
suggesting that the interaction of IL-17RD with TIR adaptors
and its inhibitory effects are SEFIR domain dependent. Since
TLR4 and TLR3 also each contain a TIR domain, we also
demonstrated that IL-17RD interacts with TLR4 (Fig. 4e) and
TLR3 (Supplementary Fig. 4b) in a SEFIR domain-dependent
manner. We next examined whether the SEFIR domain alone of
IL-17RD was sufficient to interact with the TIR domain and
manifest its inhibitory effects. A mutant encoding only the
IL-17RD SEFIR domain was thus generated and termed IL-17RD
SEFIR (Supplementary Fig. 4a). The IL-17RD SEFIR domain was
capable of interacting with MyD88 (Fig. 4f) and like the full-
length IL-17RD was also capable of interacting with other TIR
adaptors including Mal and TRIF, while IL-17RDDC, lacking the
SEFIR domain, failed to do so (Supplementary Fig. 4c,d).
Intriguingly, the IL-17RD SEFIR domain was unable to interact
with TLR4 (Fig. 4g) and TLR3 (Supplementary Fig. 4e),
suggesting that the SEFIR domain of IL-17RD is not sufficient
for mediating binding to TIR domain-containing TLRs. However,
the IL-17RD SEFIR was sufficient to effect a dose-dependent
DAPI Duolink red Merged
Unstimulated
+ scrambled siRNA
LPS
+ scrambled siRNA
LPS
+ IL-17RD siRNA 
LPS (min)
Scrambled siRNA –
– – –
– + –
IL-17RD siRNA +
-100
-45
kDa
LPS (min) 0
IB: MyD88
–110
–40
–45
kDa
–110
–100
–40
602051
IP: IL-17RD
IB: MyD88
IP: IL-17RD
IB: IL-17RD
IP: IL-17RD
IB: TLR4
IB: TLR4
IB: β-Actin
0 20 20 20
IB: IL-17RD
IB: β-Actin
30 ** *
20
10
0
Pro
be
 al
on
e
Un
stim
ula
ted LP
S
LP
S
IL-17RD siRNAScramled siRNA
%
 A
re
a 
of
 d
uo
lin
k 
re
d
re
la
tiv
e 
to
 D
AP
I b
lu
e
Figure 6 | LPS induces in situ association of IL-17RD with MyD88. (a) PBMCs from human donor blood were treated with LPS (100 ngml 1) for 0, 1, 5,
20 and 60min and cell lysates were subject to immunoprecipitation with an anti-IL-17RD antibody. Cell lysate and immunoprecipitate samples were
immunoblotted with indicated antibodies. (b) PBMCs from human donor blood were transfected with scrambled or IL-17RD-specific siRNA and cultured for
48 h prior to treatment in the absence or presence of LPS (100 ngml 1) for 20min. Cells were fixed to slides and subjected to Duolink in situ proximity
ligation assay using anti-IL-17RD and anti-MyD88 antibodies. IL-17RD/MyD88 interactions are visible as red fluorescence of the Duolink detection reagents
with nuclear staining in blue (DAPI). Images were captured using the  20 objective of a fluorescent microscope with scale bars representing 50mm.
The histogram represents the area of red Duolink signal as a percentage of area of blue DAPI signal from five random images from each of three
independent experiments. Probe alone indicates areas of signals from cells subjected to ligation assay, but in the absence of anti-IL-17RD and anti-MyD88
antibodies (five random images from each of the two independent experiments). Data are presented as the mean ±s.e.m. and were subjected to a
two-tailed paired Student’s t-test. *Po0.05; **Po0.01. The lowest-right panel demonstrates knockdown of IL-17RD expression by IL-17RD-specific siRNA
as determined by immunoblotting of cell lysates from cells treated with LPS with or without prior transfection with IL-17RD-specific siRNA or a scrambled
sequence version of this siRNA. Images have been cropped for presentation. Full-size images are presented in Supplementary Fig. 11.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7669 ARTICLE
NATURE COMMUNICATIONS | 6:6669 | DOI: 10.1038/ncomms7669 |www.nature.com/naturecommunications 9
& 2015 Macmillan Publishers Limited. All rights reserved.
inhibition of MyD88-mediated NF-kB activation (Fig. 4h).
Given these inhibitory effects of the SEFIR domain of IL-17RD,
we were keen to assess whether other SEFIR domain-containing
proteins, such as IL-17RA and Act1, could similarly inhibit
MyD88-induced activation of NF-kB. The expression of full-
length IL-17RA and Act1 or their SEFIR domains failed to affect
MyD88-induced NF-kB activation (Supplementary Fig. 4f),
suggesting that the inhibitory effects are restricted to the
IL-17RD-SEFIR domain. In addition to the SEFIR domain,
IL-17RD contains a putative TRAF6-binding site (PRERL;
residues 348–352) that is positioned immediately upstream of
the SEFIR domain39. Mutation of the conserved glutamic-acid
residue (E350A) failed to affect the ability of IL-17RD to inhibit
MyD88-induced NF-kB activation (Supplementary Fig. 4g) or to
interact with MyD88 (Supplementary Fig. 4h). Interestingly,
tyrosine residue 330 in IL-17RD had previously been described as
indispensable for the regulatory effects of IL-17RD on FGF
signalling43. Given that this residue also lies in close proximity to
the IL-17RD-SEFIR domain, we also assessed the regulatory
effects of a point mutant form of IL-17RD in which this tyrosine
residue was mutated to phenylalanine. The point mutant form
mimicked wild-type IL-17RD in its inhibitory effects on MyD88-
induced NF-kB activation (Supplementary Fig. 4i) and retained
the ability of wild-type IL-17RD to interact with MyD88
(Supplementary Fig. 4j), indicating that IL-17RD regulates FGF
and TLR signalling by distinct mechanisms. In relation to TLR
signalling, the above data collectively indicate that the IL-17RD-
SEFIR domain targets TLR pathways at the level of TIR adaptor
proteins to inhibit downstream TLR signalling.
IL-17RD disrupts signalling downstream of TIR adaptors. We
next investigated how the targeting of TIR adaptors by IL-17RD
interfered with downstream signalling pathways. We were espe-
cially keen to assess whether IL-17RD affected the recruitment of
TIR adaptors to TLRs and/or the interaction of adaptors with key
downstream effector molecules such as TRAF6. Wild-type and
Il17rd / BMDMs were treated with LPS, and lysates were
immunoprecipitated for endogenous MyD88 and assessed for co-
precipitated TLR4 and TRAF6. The loss of IL-17RD expression in
Il17rd / BMDMs had little effect on the interaction of TLR4
with MyD88 in response to LPS (Fig. 5a). However, the LPS-
induced recruitment of TRAF6 to the MyD88 signalling complex
was augmented in IL-17RD-deficient cells (Fig. 5a), suggesting
that IL-17RD tempers the ability of MyD88 to recruit down-
stream effector molecules. We investigated the functional con-
sequence of this regulatory effect of IL-17RD by assessing
polyubiquitination of TRAF6 in response to TLR4 stimulation.
LPS induced a time-dependent polyubiquitination of TRAF6 in
wild-type BMDMs but this was greatly enhanced in IL-17RD-
deficient BMDMs (Fig. 5b), indicating that the regulatory effects
of IL-17RD on MyD88–TRAF6 interaction results in decreased
ubiquitination of TRAF6. Poly(I:C)-induced polyubiquitination
of TRAF6 is also greatly augmented in IL-17RD-deficient cells
(Fig. 5c), suggesting that IL-17RD targets the TLR signalling
pathway at the level of TIR adaptors recruiting and activating
downstream effectors. This model was further supported by the
demonstration that IL-17RD directly inhibits the recruitment of
TRAF6 to the MyD88 signalling complex (Fig. 5d). Interestingly,
the IL-17RD SEFIR domain mutant is also capable of exerting
such inhibitory effects, whereas the IL-17RD DC mutant, lacking
the SEFIR domain, is ineffective (Fig. 5d). We next probed
whether the IL-17RD-SEFIR domain recognizes the TIR domain
of MyD88, and to this end we generated a truncated mutant
(amino acids 160–296) constituting the TIR domain of MyD88.
The IL-17RD-SEFIR domain mutant was capable of interacting
with MyD88 TIR (Supplementary Fig. 5a) and the interaction of
MyD88 TIR with TRAF6 was reduced with co-expression of IL-
17RD SEFIR (Supplementary Fig. 5b), suggesting that IL-17RD
SEFIR targets the TIR domain of MyD88. IL-17RA, Act1 and
their SEFIR domains were also assessed for their ability to disrupt
the MyD88/TRAF6 signalling complex. IL-17RA and the SEFIR
domains of IL-17RA and Act1 failed to replicate the ability of IL-
17RD to disrupt the MyD88/TRAF6 interaction (Supplementary
Fig. 5c) and this is consistent with our earlier data above
demonstrating the specific inhibitory effects of IL-17RD and its
SEFIR domain on MyD88-induced activation of NF-kB
(Supplementary Fig. 4f). This supports a model in which the
IL-17RD-SEFIR domain targets the TIR domain of MyD88 and
inhibits downstream recruitment of TRAF6. Interestingly, over-
expression of full-length Act1 inhibited the MyD88/TRAF6
interaction, but this is not mediated by its SEFIR domain
(Supplementary Fig. 5c) and is more likely due to its previously
characterized ability to bind to TRAF6 (ref. 44). It is possible that
this might preclude binding of the latter to MyD88.
We next probed the molecular basis to why the SEFIR domain
of IL-17RD mediates inhibitory effects on MyD88 signalling,
whereas other SEFIR domain-containing proteins such as
IL-17RA are ineffective. A previous comparison analysis of TIR
and SEFIR domains, using sequence alignments and secondary-
structure predictions, indicated similarity between these
domains31. The latter study also proposed that of the three box
regions of the TIR domain, box 1 and box 2, but not box 3, are
conserved in the SEFIR domain. Given that these box regions
facilitate homotypic TIR interactions, we performed a simple
sequence alignment (using ClustalW2 (http://www.ebi.ac.uk/
Tools/msa/clustalw2/) and BoxShade software (http://www.ch.
embnet.org/software/BOX_form.html) of the TIR domain of
MyD88 and the SEFIR domains of IL-17RA and IL-17RD to
examine differences between IL-17RA and IL-17RD in these box
regions. IL-17RA and IL-17RD showed sequence similarity in
their regions corresponding to box 2 of MyD88 (Supplementary
Fig. 5d,e), suggesting that these regions are unlikely to explain the
differential effects of the SEFIR domain in IL-17RA and IL-17RD.
However, there was more divergence in sequence between
IL-17RA and IL-17RD in the regions corresponding to box 1
and 3 of MyD88, and to this end we generated truncation
mutants of IL-17RD that lacked the box 1 (IL-17RD SEFIR
DBox1) or the box 3 region (IL-17RD SEFIR DBox3)
(Supplementary Fig. 5e). Like the full-length SEFIR domain of
IL-17RD, the IL-17RD SEFIR DBox1 mutant was capable of
interacting with MyD88, but the IL-17RD SEFIR DBox3 mutant
failed to associate with MyD88 (Fig. 5e). In addition, the IL-17RD
SEFIR DBox3 mutant failed to inhibit MyD88-induced NF-kB
activation, whereas IL-17RD SEFIR and the IL-17RD SEFIR
DBox1 mutant showed inhibitory effects (Fig. 5f). This
demonstrates that the C-terminal region of the IL-17RD SEFIR
domain, which is located at a position corresponding to box 3 of
MyD88, is critical for the functional effects of IL-17RD in
regulating MyD88-induced signalling pathways.
We next attempted to identify critical individual amino-acid
residues in the C-terminal region of the IL-17RD SEFIR.
Intriguingly, the sequence alignment shows three amino-acid
residues in this region of IL-17RD (T496, K497 and L504) that
are also present in MyD88 but not in IL-17RA (Supplementary
Fig. 5d,e). Each of these residues in the SEFIR domain of IL-17RD
were mutated to the corresponding residues in IL-17RA (T496P,
K497R and L504F) and a double mutation of the adjacent T496
and K497 residues was also performed (T496P/K497R). All four
mutants retained the ability of the SEFIR domain of IL-17RD
to associate with MyD88 (Fig. 5g), but interestingly the T496P
and T496P/K497R mutants failed to inhibit MyD88-induced
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activation of NF-kB (Fig. 5h). These data indicate that the
C-terminal region of the IL-17RD SEFIR domain is critical for its
interaction with MyD88, and T496 is a key residue for
manifesting its functional effects on MyD88 signalling. It is
especially interesting to note that unlike IL-17RD, other IL-17R
receptor family members including IL-17RA, IL-17RC and
IL-17RE contain a proline and not threonine and this may
contribute to the specificity of IL-17RD in negatively regulating
TLR signalling.
We then investigated the regulatory process by which IL-17RD
is triggered to inhibit the recruitment of TRAF6 by MyD88.
Human PBMCs were treated with LPS for indicated time points
and cell lysates were immunoprecipitated for endogenous
IL-17RD and the interaction of MyD88 assessed. LPS caused a
time-dependent interaction of IL-17RD with MyD88 (Fig. 6a).
We finally assessed whether we could detect endogenous
complexes of IL-17RD and MyD88 in situ and employed a
proximity ligation assay for this purpose. While these complexes
were not apparent in unstimulated PBMCs, LPS was shown to
promote formation of endogenous complexes of IL-17RD and
MyD88 in situ in PBMCs (Fig. 6b). It is of interest to note that
neither the co-immunoprecipitation or proximity ligation assay
showed any detectable basal interaction of endogenous IL-17RD
with MyD88, suggesting that the interaction is dependent on
TLR4 signalling triggering some mechanism to facilitate the
interaction. This is also consistent with our inability to detect any
in vitro interaction of recombinant forms of IL-17RD and MyD88
(Supplementary Fig. 6). Overall, these data suggest a new
autoregulatory network for controlling and terminating TLR
signalling pathways. The engagement of TLRs by respective
ligands results in the recruitment of TIR adaptors to the receptor
complex followed by subsequent recruitment of downstream
effectors such as TRAF6. We now propose a model in which this
is followed by TLR-induced recruitment of IL-17RD to TIR
adaptors thus inhibiting their interaction with their effectors
resulting in termination of signalling.
Discussion
While efficient functioning of TLR signalling is associated with
effective clearance of invading pathogens by specific tailored
immune responses, dysregulation of signalling can lead to chronic
inflammatory disease, autoimmunity or sepsis. As a consequence,
TLR signalling is subject to multiple levels of regulation. We now
describe a new regulatory network that involves the functional
interplay of the orphan receptor IL-17RD with TLRs. While
members of the IL-17 cytokine family and their receptors have
been previously shown to synergize with other cytokines and
TLRs to augment the inflammatory response to bacterial and
fungal infection, the present study demonstrates for the first time
that a member of the IL-17R family can negatively regulate TLR
signalling. Currently, IL-17RD is classified as an orphan receptor,
given that it has no known ligand. In the event that a ligand(s) is
subsequently discovered, it will be especially interesting to assess
whether it can regulate TLR signalling. However, even in the
absence of an identified ligand the present study demonstrates
that TLRs can promote the interaction to IL-17RD with TIR
adaptors to temper downstream signalling.
Interestingly, a recent study indicated that IL-17RD could
inhibit IL-1 and TNF signalling by sequestering the NF-kB
subunit p50 in the cytoplasm even after IL-1b- and TNF-a-
induced IkB degradation45. In addition, a splice variant of IL-
17RD was reported to promote ubiquitination of TAK1 and JNK
and p38 MAPK activation46. However, we show in Il17rd /
murine primary cells that there is an increase in TLR-induced
phosphorylation of IKKs and IkBa, suggesting that IL-17RD
targets pro-inflammatory signalling pathways upstream of IkB. In
addition, phosphorylation of IRF3 and TBK1, in response to
poly(I:C), is also enhanced in Il17rd / cells, indicating that
IL-17RD can target pathways beyond NFkB. In our model,
stimulation of TLRs promote the interaction of IL-17RD with
TIR adaptor proteins and the SEFIR domain of IL-17RD is crucial
for mediating this interaction. A mutant lacking the SEFIR
domain failed to interact with MyD88, Mal and TRIF and loss of
this interaction led to diminished inhibitory effects on NF-kB
activation. In contract, the SEFIR domain alone was capable of
targeting adaptors and manifesting inhibitory effects on
downstream signalling. The discovery that the TIR domain of
TLRs and IL-1Rs and the SEFIR domain of IL-17Rs are part of a
larger domain superfamily highlights the importance of such a
motif in innate immune signalling31. While a previous report
indicated that IL-17R signalling can co-operate in a positive
manner with some TLRs47, we now propose that the IL-17RD-
SEFIR domain negatively regulates TIR domain-containing TLRs,
and the region of the IL-17RD-SEFIR domain that corresponds to
box 3 of TIR domains is central to this function. It is also
noteworthy that mutation of a highly conserved threonine residue
in this region abolished the functional effects of the IL-17RD
SEFIR domain, and it will be interesting to assess whether this
residue is subject to phosphorylation and thus regulation by post-
translational modification. Binding of IL-17RD to MyD88 failed
to inhibit the adaptor from interacting with TLR4 but prohibited
TRAF6 recruitment to the complex, constituting a novel negative
regulatory mechanism of TLR signalling. As a consequence,
polyubiquitination of TRAF6 was greatly increased in Il17rd /
macrophages and dendritic cells in response to LPS and poly(I:C).
This translated into enhanced downsteam activation of NFkB
and IRF3 and induction of pro-inflammatory cytokines that
ultimately manifested with Il17rd / mice being more
susceptible to the lethal effects of LPS and poly(I:C). Such
studies emphasize the physiological relevance of IL-17RD in
controlling exaggerated inflammatory responses.
In addition to elucidating a new regulatory network of TLR
signalling and a new function for IL-17RD in innate immunity,
our findings also emphasize the intricate cross-talk between
innate immune signalling pathways. Recent findings have shown
that IKKi and TBK1, key kinases in activating IRFs and regulating
type-I IFN expression, regulate IL-17 signalling by directly
phosphorylating the adaptor molecule Act1 (refs 48,49). In
addition, IL-17 is produced in response to avian influenza virus
and respiratory syncytial virus and synergizes with anti-viral
signalling pathways47. These discoveries demonstrate the growing
complexity of IL-17 signalling and its impact on other signalling
pathways. Collectively, our data highlight a key role for IL-17RD
in facilitating homeostasis of the innate immune response.
IL-17 receptors and TLRs are highly conserved throughout
evolution, and high sequence identity among related domains
makes it tempting to speculate that they derived from the same
ancestral precursor receptor. Given such a scenario, it is plausible
that IL-17RD, possibly the most evolutionarily ancient of the
IL-17R family50, retained the ability to tightly regulate other IL-17
and TLR members. TLRs and their ancestral proteins play key
dualist roles as mediators of early development in embryogenesis
while also fulfilling seminal roles in mediating innate immunity in
adult life. In parallel, IL-17RD now emerges as not only a negative
regulator of FGF signalling in early developmental patterning but
also as a key modulator of innate immune signalling. This
highlights the remarkable exploitation of regulatory networks for
diverse purposes at different stages of life.
Given its negative role in both IL-17R and TLR signalling, it
will be of interest to explore whether dysregulated IL-17RD
expression and/or activity contributes to chronic inflammatory
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disease. Indeed, two separate single-nucleotide polymorphisms
have been identified in the Il17rd gene, one which contributes to
an increased risk in psoriasis51 and one with a borderline
association with Crohn’s disease52. The present study provides
the first insight into such potential regulatory effects of IL-17RD
in disease.
Methods
Plasmids and reagents. Full-length IL-17RD and IL-17RD DC were cloned as
previously described32. IL-17RD E350A, IL-17RD Y330F, IL-17RD SEFIR T496P,
IL-17RD SEFIR K497R, IL-17RD SEFIR L504F and IL-17RD SEFIR T496P/K497R
were generated by site-directed mutagenesis using pfu Turbo Thermo Fisher
Scientific (Waltham, MA). MyD88 TIR (amino acids 160–296), IL-17RD SEFIR
DBox1 and IL-17RD SEFIR DBox3 were generated using Phusion High-Fidelity
DNA polymerase from New England Biolabs (Ipswich, MA). IL-17RA, IL-17RA
SEFIR, Act1 SEFIR, IL-17RD SEFIR and mIL-17RD were generated by GenScript.
TRAF6 was from Tularik (San Francisco, CA). TK Renilla-luciferase reporter
construct (phRL-TK) was from Promega (Madison, WI). The NF-kB-luciferase
reporter construct and constructs encoding MyD88 and Mal were gifts from
Professor Luke O’Neill (Trinity College Dublin, Ireland). The pFR-luciferase and
constructs encoding TLR4, TLR3, TRIF and TRAM were from Professor Andrew
Bowie (Trinity College Dublin). The IKKi, TBK1 and IRF3/7 Gal4 reporter
constructs were gifts from Professor Kate Fitzgerald (The University of
Massachusetts Medical School, Worcester, Massachusetts, USA). LPS was from
Enzo Life Sciences (Exeter, UK), poly(I:C), Pam2CSK, Pam3CSK, Zymosan,
Flagellin, CLO97 and CpG were from Invivogen (San Diego, CA). Anti-human
IL-17RD antibodies used were from R&D systems (Minneapolis, USA) and
Phoenix Pharmaceuticals (Burlingame, CA) (1:250 working dilution). Anti-murine
IL-17RD antibody (1:250) was from Thermo Fisher Scientific. Anti-phospho IkBa
(1:500), anti-phospho IKK (1:1,000), anti-IKK (1:1,000), anti-phospho TBK1
(1:750), anti-TBK1 (1:750), anti-phospho IRF3 (1:750), anti-phospho p38 (1:750),
anti-p38 (1:750), anti-phospho ERK (1:750), anti-ERK (1:750), anti-phospho JNK
(1:750), anti-JNK (1:750) and anti-Myc antibodies (1:1,000) were from Cell
Signalling Technology Inc. (Danvers, MA). The anti-HA antibody (1:500) was from
Covance Inc. (NJ, USA). Anti-GST (1:1,000), anti-b-actin (1:8,000) and anti-FLAG
(1:2,000) antibodies and the Duolink In Situ Red Starter kit Goat/Rabbit were
supplied by Sigma-Aldrich (St Louis, USA). Anti-IkBa (1:500), anti-IRF3 (1:500),
anti-TRAF6 (1:500), anti-MyD88 (1:250), anti-TLR4 (1:500), anti-ubiquitin (1:500)
and anti-p65 (1:500) antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA). Recombinant human MyD88 was from Novus Biologicals (Littleton, CO) and
recombinant human IL-17RD was from Origene (Rockville, MD).
Mice. IL-17RD-deficient mice were generated by the German Genetrap
Consortium using its proprietary technology (clone ID: D065E01) as previously
described32. Briefly, a gene trap vector was incorporated into the Il17rd gene after
the first exon in embryonic stem cells of 129S2/SvPas origin. Embryonic stem cells
were microinjected into female mice of C57BL/6 background and heterozygous F1
progeny were intercrossed to obtain Il17rd  / mice. Il17rdþ / mice were bred
to generate age- and sex-matched Il17rdþ /þ and Il17rd / mice for experiments.
Breeding, colony expansion and maintenance were performed in the Bioresource
facility of the National University of Ireland (NUI), Maynooth. All animals were
housed in individually ventilated cages with high-efficieny particulate air filters. All
animal experiments were performed in accordance with the regulations and
guidelines of the Irish Department of Health and protocols approved by the
Biomedical and Life Sciences Research Ethics committee of NUI Maynooth.
Cell culture. HEK293 and U373 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% (v/v) fetal bovine serum (FBS), 100Uml 1
penicillin and 100 mgml 1 streptomycin. HEK293 TLR3 cells and HEK293
TLR4 cells were maintained in Blasticidin (Invivogen, 10 mgml 1) or G418
(500 mgml 1), respectively. THP-1 suspension cells were grown in Roswell Park
Memorial Institute (RPMI) plus GlutaMAX-I medium (Gibco) supplemented with
10% (v/v) FBS, and penicillin/streptomycin (100 unitsml 1 and 0.1mgml 1,
respectively).
Human PBMCs from healthy volunteers were extracted from buffy coats
provided by the Irish Blood Transfusion Service. PBMCs were isolated using the
Ficoll-Hypaque isolation technique and plated in complete RPMI 1640 medium.
For the preparation of primary MEFs, Il17rdþ / mice were bred to generate
Il17rdþ /þ and Il17rd / embryos. Embryos were dissected from pregnant
females at day 13 post coitum. MEFs were isolated by standard procedure and
cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% (v/v) FBS
for 3 days. To isolate BMDMs or BMDCs, tibias and femurs from Il17rdþ /þ and
Il17rd / mice were removed using a sterile technique and the bone marrow was
flushed with fresh medium. To obtain macrophages, cells were plated in medium
supplemented with M-CSF (20 ngml 1) and maintained at 37 C in a humidified
atmosphere of 5% CO2 for 4–6 days. To obtain myeloid dendritic cells, cells were
plated in medium supplemented with GM-CSF (10 ngml 1) and maintained at
37 C in a humidified atmosphere of 5% CO2 for 6–8 days. Medium was replaced
with fresh supplemented media every 3 days. All cells were maintained at 37 C in a
humidified atmosphere of 5% CO2.
Luciferase reporter assay. HEK293 cells were seeded (1.5 105 cellsml 1)
in 96-well plates (200 ml per well) for 24 h. Cells were then transfected using
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instruction,
with constructs encoding NF-kB-regulated firefly luciferase (80 ng) or pFR firefly
luciferase reporter construct (60 ng) with IRF3 (30 ng) or IRF7 (25 ng) (both fused
downstream of the yeast Gal4 DNA-binding domain), constitutively expressed TK
Renilla-luciferase reporter construct (phRL-TK) (40 ng) (Promega Biosciences) and
varying amounts of expression constructs as indicated. Total DNA was kept
constant (200 ng per well) using the appropriate empty vector. Cell extracts were
generated 24 h post transfection using Reporter Lysis Buffer (Promega Biosciences)
and extracts were assayed for firefly luciferase and Renilla-luciferase activity
using the Luciferase Assay system (Promega Biosciences) and coelenterazine
(0.1 mgml 1 Insight Biotechnology Ltd.), respectively. Luminescence was mon-
itored with the Glomax microplate luminometer (Promega). Data are presented as
fold stimulation of firefly luciferase expression relative to unstimulated cells. For
siRNA knockdown studies, HEK293 TLR3 and TLR4 cells were seeded (1.5 105
cellsml 1; 3ml) in six-well plates and grown for 24 h. Cells were then transfected
using Lipofectamine 2000 with siRNA and luciferase constructs for 48 h. Cells were
treated as indicated and assayed for luciferase activity.
Lentiviral production and transduction. HEK 293T cells were seeded (2 105
cellsml 1; 3ml) in six-well plates and grown for 24 h to B80% confluency.
Cells were transfected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions with the packaging plasmid pCMV-dR 8.91 (1 mg),
envelope plasmid VSV-G (1 mg) and IL-17RD sh-pLKO.1 vector (2 mg) or control
shRNA (Sigma-Aldrich): IL-17RD shRNA 50-CCGGCCAGTCTTGGAGAAATTT
GATCTCGAGATCAAATTTCTCCAAGACTGGTTTTTG-30 (NM_017563.1-
1819s1c1). Conditioned medium was changed 24 h post transfection and replaced
with fresh growth medium containing 30% (v/v) FBS for a further 24 h. The
lentiviral-containing medium was harvested and replenished every 24 h for 72 h.
U373 and THP-1 cells, seeded (2 105 cellsml 1; 3ml) in six-well plates,
were transduced with 600 ml lentivirus-containing medium with hexadimethrine
bromide (8mgml 1) and incubated at 37 C for 24 h prior to positive selection of
cells with integrated shRNA constructs with puromycin (8 mgml 1).
ELISA and type-I IFN bioassay. Primary MEFs and BMDMs were seeded in
(2 105 cellsml 1; 1ml) 12-well plates or in (5 105 cellsml 1; 200 ml) 96-well
plates and grown for 24 h. Cells were subsequently stimulated with various ligands
for the indicated time points as described in figure legends. Conditioned media was
collected from each well and measured for levels of TNF-a, IL-6, RANTES, KC
(DuoSet kits (R&D Systems)), IL-12/IL-23 p40 (Biolegend) and IFN-b using
the Mesoscale Discovery System and murine type-I IFN by blue sensor cells
(Invitrogen) as per the manufacturer’s instructions.HEK293, or U373 and THP-1
cells stably transfected with control or IL-17RD-specific shRNA were seeded
(2 105 cellsml 1; 200 ml) in 96-well plates and grown for 24 h. In some
experiments cells were transfected, using Lipofectamine, with siRNA targeting
IL-17RD (sense sequence: 50-GGAGCAAACUACAGAGAUGTT-30) or with
scrambled siRNA (sense sequence: 50-GGACAGAACACUAGAUGAGTT-30)
(20 nM) (Ambion) for 48 h. Cells were subsequently stimulated with various
ligands for the indicated time points and conditioned media was collected from
each well and measured for levels of TNF-a, IL-6, IL-8, RANTES (DuoSet kits
(R&D Systems)) and IP-10 (ELISA development Kit (Peprotech)). PBMCs were
seeded (2 105 cellsml 1; 200 ml) in 96-well plates and grown for 24 h prior to
transfection with siRNA for 48 h with Lipofectamine 2000 (Invitrogen). Cells were
treated as indicated and supernatants were measured for levels of IL-8 (DuoSet kits
(R&D Systems)) and IFN-b (Mesoscale Discovery System).
TLR-induced death and cytokine production in mice. Ten to twelve-week-old
male Il17rdþ /þ and Il17rd / mice were administered with LPS (20mg kg 1)
or poly(I:C) (5mg kg 1) by i.p. injection for 16 h. Control mice were injected with
endotoxin-free PBS. Mice were sacrificed 16 h post administration and serum was
taken for enzyme-linked immunosorbent assay (ELISA) analysis. Spleens were
snap-frozen in liquid nitrogen and stored at  80 C for RNA analysis. Livers were
fixed in 10% formalin, paraffin-embedded, sectioned at 5 mm and stained with
haematoxylin and eosin. The pathologist (J.J.C.) was blinded to the genetic and i.p.
treatment of the mice. Ten to twelve-week-old female Il17rdþ /þ and Il17rd /
mice were administered with LPS (20mg kg 1) or poly(I:C) (0.01 mg per g body
weight) with D-GAL (0.7mg per g body weight) by i.p. injection using PBS and
D-GAL as respective controls. Mice were observed and weighed twice daily for the
duration of the experiment. Mice that became moribund were considered to have
reached the end point of the experiment and were euthanized. Power analysis
was used to calculate required sample size based on a Power of 0.9 and probability
of 0.05.
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EMSA. BMDMs, MEFs or BMDCs were grown in 90-mm culture dishes for 24 h
and were stimulated with LPS (10 or 100 ngml 1) or Poly(I:C) (5 mgml 1),
respectively. Nuclear extracts were generated as previously described51. Nuclear
extracts (5 mg) were incubated with LI-COR IRDye 700-labelled oligonucleotide
containing the NF-kB-binding site 5-AGTTGAGGGGACTTTCCCAGGC-30 (kB
site underlined) or IRDye 700-labelled oligonucleotide containing the IFNb PRD
I/III-binding site 50-GTAAATGACATAGGAAAACTGAAAGGGAGAAGTGAA
AGTGG-30 according to the manufacturer’s instructions. For competitive analysis,
a non-labelled oligonucleotide of the same sequence was added to the extracts
at room temperature (RT) for 15min prior to incubation with labelled
oligonucleotide. Samples were subjected to electrophoresis on a 4% native
polyacrylamide gel for 2 h at 70V and subsequently analysed, and images captured
using the Odyssey Infrared Imaging System (LI-COR Biosciences).
Retroviral production and transduction. HEK 293T cells were seeded (2 105
cellsml 1; 3ml) in six-well plates and grown for 24 h to 80% confluency. The cells
were transfected using Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions, with the packaging vector (1mg) and MSCV plasmid (1mg)
or MSCV-mIL-17RD (1mg). The cells were then incubated for an additional 24 h.
The retroviral-containing medium was harvested and stored at 20 C. Fresh growth
medium containing 30% (v/v) FBS was added to cells and incubated for another
24 h. The virus-containing medium was again harvested and stored for use. WT
MEFs and IL-17RD-deficient MEFs were seeded (3 105 cellsml 1; 6ml) in
25-cm2 flasks and grown for 4 h. The growth medium was then removed and
replaced with fresh medium containing hexadimethrine bromide (8mgml 1) and
1ml retrovirus-containing medium from above. The flasks were incubated at 37 C
for 48 h prior to experiments.
Immunoblot analysis. BMDMs, MEF cells or U373 cells stably transfected with
IL-17RD shRNA or control shRNA (3 105 cellsml 1) were seeded in six-well
plates and grown for 24 h. Cells were stimulated with LPS (100 ngml 1) or
Poly(I:C) (25mgml 1) for different time points as indicated in the figure legends.
Cells were washed in 1ml of ice-cold PBS and lysed in 100 ml of NP-40 lysis buffer
(50mM Tris-HCl, pH 7.5, containing 150mM NaCl, 0.5% (w/v) igepal, 50mM
NaF, 1mM Na3VO4, 1mM dithiothreitol (DTT), 1mM phenylmethylsulfonyl
fluoride (PMSF) and complete protease inhibitor mixture (Roche)). The cell lysates
were centrifuged at 12,000g for 10min, supernatants were collected and subjected
to western blotting using the indicated antibodies. Immunoreactive bands were
detected using the Odyssey Infrared Imaging System, according to the instructions
of the manufacturer.
Co-immunoprecipitation analysis. Cells were seeded (2 105 cellsml 1; 3ml or
10ml) in six-well plates or 90-mm Petri dishes and transfected, using Lipofecta-
mine 2000, with defined amounts of various expression constructs as described
above. Cells were washed with pre-chilled PBS (1ml) and then lysed with pre-
chilled lysis buffer (250 ml) (50mM HEPES, pH 7.5 containing 1mM EDTA, 10%
(v/v) glycerol, 0.05% (w/v) CHAPS, 0.5% (v/v) Triton-X and 250mM NaCl, 1mM
Na3VO4, 1mM DTT, 1mM PMSF and complete protease inhibitor mixture
(Roche)) for 30min on a rocker at 4 C. For co-immunoprecipitations with TLR3
and TLR4, a ‘TLR’ lysis buffer (150mM NaCl, 50mM Tris-HCL (pH 7.6), 4mM
EDTA, 1% (w/v) Brij, 0.5% (w/v) n-octyl-b-D-glucoside and 0.5% Triton-X-100
(v/v)) was used. Lysates were centrifuged at 12,000 g for 10min at 4 C. Aliquots
(50 ml) were retained for immunoblotting while the remaining supernatants were
removed to fresh pre-chilled tubes. Samples were incubated overnight with the
appropriate antibody (2 mg) at 4 C with rocking. This was followed by the addition
of protein A/G agarose beads (30ml per sample). Incubations were placed at 4 C
with rocking for 4 h. Immunoprecipitates were collected by centrifugation at
1,000 g for 5min at 4 C and the beads were then washed four times with lysis
buffer (600 ml) lacking the protease inhibitor mixture. The beads were resuspended
in 2 SDS–polyacrylamide gel electrophoresis (PAGE) sample buffer (40ml) and
incubated for 30min at RT. Samples were centrifuged at 16,000 g for 2min,
subsequently boiled at 100 C for 5min and subjected to immunoblotting. The
immunoreactive bands were detected and images captured using Odyssey Infrared
Imaging System.
TRAF6 polyubiquitination studies. Primary BMDMs or BMDCs were seeded in
cell culture 90-mm dishes (5 105 cellsml 1; 1 106 cellsml 1) and grown for
24 h. Cells were stimulated with LPS or Poly(I:C) for designated times. Cells were
washed in 1ml of ice-cold PBS and lysed in 200 ml of lysis buffer (50mM HEPES,
pH 7.5 containing 1mM EDTA, 10% (v/v) glycerol, 0.05% (w/v) CHAPS, 0.5%
(v/v) Triton-X and 250mM NaCl, 1mM Na3VO4, 1mM DTT, 1mM PMSF and
complete protease inhibitor mixture (Roche)). The cell lysates were centrifuged at
12,000g for 10min and supernatants were collected. Aliquots (20 ml) of these
whole-cell lysates were retained for immunoblotting while the remaining
supernatants were treated with 1% SDS and incubated at 95 C for 5min to
dissociate protein–protein interactions. Samples were then diluted 10-fold with
lysis buffer prior to incubation overnight with the indicated antibody (2 mg) at 4 C
with rocking. This was followed by the addition of protein A/G agarose beads
(30 ml per sample). Incubations were placed at 4 C with rocking for 24 h.
Immunoprecipitates were collected by centrifugation at 12,000g for 1min at 4 C
and the beads were then washed four times with lysis buffer (600 ml) lacking the
protease inhibitor mixture. The beads were resuspended in 2 SDS–PAGE sample
buffer (40 ml) and incubated for 20min at RT. Samples were centrifuged at 12,000 g
for 1min, subsequently boiled at 100 C for 5min and subjected to SDS–PAGE and
immunoblotting using the indicated antibodies. The immunoreactive bands were
detected and images captured using Odyssey Infrared Imaging System or using an
enhanced chemiluminescent substrate.
In vitro co-immunoprecipitation assay. Full-length recombinant human
IL-17RD-Myc (1.5 mg) was incubated with full-length recombinant human
MyD88-GST (1 mg) for 1 h at 4 C with rocking in reaction buffer (25mM Tris-
HCl, 100mM NaCL, 3% (v/v) glycerol, 0.05% (v/v) Triton-X). Samples were then
incubated with a specific anti-GST antibody (1 mg) 1 h at 4 C with rocking. This
was followed by the addition of protein A/G agarose beads (30 ml per sample) with
rocking for 1 h. Immunoprecipitates were collected by centrifugation at 12,000 g for
1min at 4 C and the beads were then washed three times with reaction buffer.
Washes were saved and flow-through protein was concentrated using Amicon
Ultra filters (0.5ml) (Millipore). The beads were resuspended in 2 SDS–PAGE
sample buffer (40ml) and incubated for 20min at RT. Samples were centrifuged
at 12,000g for 1min, subsequently boiled at 100 C for 5min and subjected to
SDS–PAGE and immunoblotting using the indicated antibodies.
RNA isolation and quantitative PCR. BMDMs, MEFs and U373 cells stably
transfected with control or IL-17RD shRNA were seeded (2 105 cellsml 1; 3ml)
into six-well plates and grown for 24 h. Cells were then treated with various ligands
for the indicated time points. Cells were washed in PBS and RNA was extracted
using Tri-Reagent (Sigma) according to the manufacturer’s instructions. Total
RNA was also isolated from spleens, had been snap-frozen in liquid nitrogen and
homogenized in 1ml of Tri-Reagent. After DNase I digestion, complementary
DNA was generated from normalized RNA using AMV reverse transcriptase
(Promega). Samples were assayed by quantitative real-time PCR using Brilliant
SYBR Green QPCR Master mix (Stratagene). For the amplification of the specific
genes, the following primers were used: hIfnb1 forward 50-GACCAACAAGTGTC
TCCTCCAAA-30 and reverse 50-CTCCTCAGGGATGTCAAAGTTCA-30 ; mIfnb1,
forward 50-GGAGATGACGGAGAAGATGC-30 and reverse 50-CCCAGTGCTG
GAGAAATTGT-30; mTnf, forward 50-CATCTTCTCAAAATTCGAGTGACAA-30
and reverse 50-TGGGAGTAGACAAGGTACAACCC-30 ; hIl8, forward 50-CACCG
GAAGGAACCATCTCACTGT-30 and reverse 50-TCCTTGGCAAAACTGCACC
TTCA-30 ; mCxcl1, forward 50-AGACCATGGCTGGGATTCAC-30 and reverse
50-CAAGGGAGCTTCAGGGTCAA-30 ; mIl6, forward 50-ACAACCACGGCC
TTCCCTAC-30 and reverse 50-TCCACGATTTCCCGAGAACA-30 ; mCcl5,
forward 50-GGAGATGAGCTAGGATAGAGGG-30 and reverse 50-TGCCCAT
TTTCCCAGGACCG-30 ; hIl17rd, forward 50-CTGTCTCTGCCACTGATGGA-30
and reverse 50-AGAGGAGCTTGGAAGGAAGG-30; mIl17rd, forward 50-ACCTG
AGCACCAAGTACAAGCTCA-30 and reverse 50-TGCAAATGGCAACATACAG
GGAGC-30 ; mCxcl10, forward 50-GACGGTCCGCTGCAACTG-30 and reverse
50-GCTTCCCTATGGCCCTCATT-30 ; mInos forward 50-CAAGCACCTTGGAA
GAGGAG-30 and reverse 50-AAGGCCAAACACAGCATACC-30; mHprt, forward
50-GCTTGCTGGTGAAAAGGACCTCTCGAAG-30 and reverse 50-CCCTGAAG
TACTCATTATAGTCAAGGGCAT-30 ; hHprt, forward 50-AGCTTGCTGGTGAA
AAGGAC-30 and reverse 50-TTATAGTCAAGGGCATATCC-30.
Confocal microscopy. HEK293 TLR4 cells were seeded (2 105 cellsml 1) in
four-well chamber slides (Lab-Tek, Nunc A/S, Roskilde, Denmark) and grown for
24 h to 80% confluence. Cells were transfected using Lipofectamine 2000 with
plasmids encoding MyD88-pEGFP with IL-17RD-pRFP. Processing of samples was
performed on ice. Medium was removed, and the cells were gently washed three
times in chilled 1 PBS (500 ml). Cells were then fixed by the addition of 2% (v/v)
paraformaldehyde (500 ml) for 20min. Cells were washed three times with PBS.
Nuclei were stained with an aliquot (500 ml) of 40 ,6-diamidino-2-phenylindole
(DAPI) (1.5 mgml 1; Sigma) for 2min. Cells were mounted with Vectashield
hardset mounting medium (Molecular Probes Inc.). Confocal images were cap-
tured using the  40 or  63 objective lens on the UV Zeiss 510 Meta System laser
scanning microscope equipped with the appropriate filter sets. Acquired images
were analysed using the LSM 5 browser imaging software.
In situ proximity ligation assay. PBMCs were seeded (1 106 cellsml 1; 10ml)
in 90-mm Petri dishes and transfected, using Lipofectamine 2000, with 40 nM of
scrambled or IL-17RD-specific siRNA. Cells were adhered to poly-l-lysine (Sigma)-
coated microscope slides and fixed using acetone/methanol (1:1) at  20 C for
10min. Slides were treated with a blocking buffer (PBS containing 1% (w/v) BSA)
for 30min followed by incubation with goat anti-human IL-17RD (10 mgml 1)
(R&D) and rabbit anti-human MyD88 (1:100 dilution) (Enzo) primary antibodies
in blocking buffer for 1 h at RT. Slides were then incubated with Duolink PLA
Rabbit MINUS and PLA Goat PLUS probes (Sigma) for 1 h at 37 C in a humidity
chamber followed by ligation and amplification steps as described by manu-
facturers of the Duolink In Situ Red Starter kit Goat/Rabbit (Olink Bioscience,
Uppsala, Sweden). Ligations were visible as red fluorescence of the Duolink
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detection reagents with nuclei staining blue from the DAPI-containing mounting
medium. Images were captured using the  20 objective of a fluorescent micro-
scope. Image analysis was performed using Olympus cellSens Dimension 1.9
software and interactions quantitated as areas of red Duolink signal normalized to
areas of blue DAPI signal.
Statistical analysis. Data are expressed relative to untreated cells and are the
means ±s.e.m. of triplicate determinations from three independent experiments.
For comparison between two groups, Student’s two-tailed paired t-test was used.
For comparison between serum and tissue samples from mice or PBMCs from
different donors Student’s two-tailed unpaired t-test was used. The log-rank test
was used for survival studies. A P value of o0.05 was considered significant.
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